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1057-148 Lower Dietary Polyunsaturated to Saturated Fat Ratio Is 
Associated With Increased Visceral Adiposity 
Jidona Sunq Jamie R. DeRegis. Anita C. Bather, Katherine L. Turner, Paul S. Hees, 
Mark D. Keleman, Pamela Ouyang, Kerry J. Stewart, Johns Hopkins University School of 
Medicine, Baltimore, MD 
Background: Increased visceral fat is associated with increased insulin resistance and 
cardiovascular risk factors. While dietary fat is related to cardiovascular risk factors, less 
is known about the relationship between dietary fat and its components to visceral fat. 
Methods: Subjects (n=84.46 wcmen and 38 men) were aged 55 to 75 years, sedentary, 
without clinical cardiovascular disease, nonsmoking and without diabetes. Diet was 
assessed by analyzing 3-day food records. Body composition was assessed with a vari- 
ety of techniques including anthropometry, total body fat by dual energy X-ray absorpti- 
ometry (DEXA), and abdominal fat distribution by MRI. 
Results: Among dietary intake, % saturated fat energy (r=0.23, ~~0.05) and polyunsatu- 
rated fat i saturated fat ratio (PUFA’SFA ratio) (r=-0.33, ~~0.01) were correlated to 
abdominal visceral fat. Waist circumference (rc0.71, pcO.001) and total body fat (r=O.40. 
~~0.01) correlated to visceral fat. Men had more visceral fat then women. (162 +/- 56 vs. 
124 +I- 56 cm2, ~~0.01) Age did not correlate to visceral fat. In multivariate analysis, 
lower PUFAISFA ratio was independently associated (p.zO.05) with higher visceral fat 
after adjustment for gender and total body fat. 
Conclusion : A higher dietary consumption of polyunsaturated fat relative to saturated fat 
was an independent predictor of lower visceral fat. Modification of type of fat intake may 
have an impact in specifically reducing visceral fat in addition to the well-known beneficial 
influence to serum lipid proflle. 
1057-l 49 Post-Prandial Lipid and Lipoprotein Responses in 
Patients Taking HIV Protease Inhibitors 
James H. SteiQ Michelle A. Merwood, Jennifer L. Bellehumeur, James M. Sosman, 
University of Wisconsin Medical School, Madison. WI 
Background: The dyslipidemia associated with human immunodeficiency virus protease 
inhibitors (HIV Pls) is associated with increased levels of triglyceride-rich lipoproteins and 
cholesterol-nch remnants. The purpose of this study was to determine if use of HIV Pls 
increases post-prandial lipemia. 
Methods: After a 12.hour fast, 39 HIV+ and 10 HIV- euthyroid, non-diabetic subjects 
ingested an oral lipid load consisting of a milkshake that contained (mean+standard 
error) lOl*l grams of fat. All HIV+ subjects were on stable anti-retroviral regimens; 24 
were taking Pls, 15 were not taking Pls. Serum samples were obtained at baseline prior 
to the fat load, then every 2 hours for 10 post-prandial hours. Lipid mass concentrations 
of 16 lipoprotein fractions, average particle sizes, and particle concentrations were quan- 
tified by nuclear magnetic resonance spectroscopic lipoprotein subclass analysis (Lipo- 
Science, Inc., Raleigh, North Carolina). 
Results: HIV- subjects were younger (3153 years. p<O.OOl) than HIV+ subjects taking 
Pls (43t2 years) or not (41*2 years). ApoE phenotypes were similar in all 3 groups. The 
age-adjusted areas under the concentration curves (AUCs) for intermediate-density lipo- 
proteins (IDL) were significantly higher for HIV+ subjects taking Pls than for HIV+ sub- 
jects not on Pls and HIV- controls (p<O.O05). The AU& for triglycerides was higher I” 
subjects on Pls (p=O.O25), and tended to be higher in HIV+ subjects not on Pls 
(p=O.O64), as compared to HIV- controls. AUC’s for large very low-density lipoproteins 
and total cholesterol also tended to be higher in both HIV+ groups than controls (pcO.08). 
In subjects on Pls. increased chylomicrons were observed in the late post-prandial 
period, suggesting delayed clearance (p<O.OS). 
Conclusion: Individuals with HIV Infection have increased post-prandial hyperlriglyceri- 
demia. Individuals taking Pls have impaired clearance of IDL. Clearance of chylomicrons 
may be decreased in individuals taking Pls. Individuals treated for HIV infection, espe- 
cially those taking Pls. may be at increased vascular risk due to alimentary hyperlipi- 
demia. 
1057-l 50 Improved Lipid Profile and Reduced Lipid Peroxidation 
With Soy Milk in Patients With Primary 
Hypercholesterolemia 
Llliana Bricarello, Francisco A. Fonseca. Marc& C. Bertolami, Andre Faludi, Nelson 
Kasinski, Leonor E. Pinto, Waldir G. Relvas, Maria C. Izar, Silvia S. Ihara, Antonio C. 
Carvalho. Federal University of Sao Pa&, Sao Pa&, Brazil, Dante Pazzanese Institute 
of Cardiology, Sao Paula, Brazil 
Background: Soy protein. in addition to ATP Ill Therapeutic Lifestyle Changes (TLC) 
diet, has been reported as a therapeutic option to optimize LDL-cholesterol lowering. 
Therefore, this study was aimed to assess whether the consume of soy milk could add 
significantly to lipid profile and lipid peroxidation in comparison with low fat cow milk, in 
patients with primary hypercholesterolemia. Methods and Results: A double-blind. ran- 
domized. crossover study evaluated 60 men and women with primary hypercholester- 
olemia under TLC diet for at least six weeks. Lipid profile was obtained at baseline, 6 and 
12 weeks with the patients randomly assigned to receive first one liter per day of either 
soy milk or low fat cow milk. No significant differences in total calories (60 vs. 57 kcal) or 
cholesterol (0 vs. 1 mg) were identified when comparing the two milk compositions 
(amount per 200 ml). However, soy milk had higher fat (3,5 vs. 0.01s) and smaller carbo- 
hydrate content (1 vs. 8.6 g). Patients were carefully monitored regarding dietary intake. 
CHANGES IN LIPIDS AND TBARS 
Period of Total LDL- HDL- TG TBARS 
treatment cholesterol cholesterol cholesterol (“‘9’ (nM) 
(@dL) (@dL) (mgldL) dL) 
Base line 241 f 5 157+4 58 * 2 136*9 1.8* 
0.1 
Soy milk 237 f 4 148+4’ 62+2# 133*8 1.5+0.1 
Cow milk 240 f 4 157*4 57 * 2 134*9 1.9* 
0.1 
Values are means f SEM; TG = Triglycerides; ‘~~0.05 vs. base line and cow milk; 
#p<O.Ol vs. base line and cow milk. 
Conclusions: Soy milk improved lipid profile and attenuated lipid peroxidatlon. Consid- 
ering the large use of milk in modern societies, this strategy could be suggested in the 
prevention of cardiovascular disease, particularly in hypercholesterolemic populations. 
1057-151 Effects of Step I Diet on Nitric Oxide Bioactivity, Oxidant 
Stress, Inflammation, Plaque Stabilization, and 
Hemostasis in Hypercholesterolemic Patients With 
Coronary Artery Disease 
Kwana K. Koh, Jeong Y. Ahn, Ji W. Son, Gachon Medical School, Incheon, South Korea 
Background: We Investigated the effects of American Heart Association Step I Diet on 
endothelial function- nitric oxide (NO) bioactivity and serological markers of Oxidant 
stress, inflammation, plaque stabilization, and hemostasis. 
Methods: We administered American Heart Association Step I Diet during 14 weeks to 
50 patients with coronary artery disease. ‘=P<0.05;‘*=P~0.01;“‘=P<0.001 vs. Baseline. 
Data= mean+SD. 
Results Diet therapy significantly reduced lipoproteins levels, and improved the percent 
flow-mediated dilator response (FMD) to hyperemia from 4.46+1.66 to 5.29+1.81 by 
25+36% (PcO.001) and increased plasma levels of nitrate from 64t28 to 79+42 uM by 
36*74% (P=O.O49), and reduced plasam levels of malondialdehyde (MDA), a marker of 
free radical from 1.75eO.71 to 1.52eO.54 uM by 7*30% (P=O.Oll). Diet therapy, how- 
ever, did not significantly change plasma levels of monocyte chemoattractant protein 
(MCP-I), intercellular adhesion molecule (ICAM-I), and C-reactive protein, and total 
matrix metalloproteinase (MMP)-9 and MMP-3, and fibrinogen and tissue factor activity 
and tissue factor pathway inhibitor activity. 
Conclusions; Diet therapy improved endothelium-dependent vasodilation with increase 
of plasma nitrogen oxide and reduction of oxidant stress. However, Diet therapy did not 
change markers of inflammation, plaque stability, and hemostasis. 
1057-220 Fluvastatin Prevents Cardiac Events Following 
Successful Percutaneous Coronary Intervention in 
Patients With Multivessel Disease: The Lescolfi 
Intervention Prevention Study 
Pedro A. Lemos. G. Boxho, Dick Goedhan, B. CYNeil, J. P. Broustet, G. Berghoefer, C. 
Alonso, A. Boehmer, Pim de Feyter, Patrick W. Serruys. Erasmus University Medical 
Center, Rotterdam, The Netherlands 
Background: Patients with multivessel disease have a worse prognosis after percutane- 
ous coronary intervention (PCI) than those with single-vessel disease. This analysis eval- 
uated the impact of early fluvastatin treatment on major adverse cardiac events (MACE) 
!n patients with coronary heart disease and multivessel disease, who had been enrolled 
into the Lescola Intervention Prevention Study (LIPS), a ms]or prospective randomized 
clinical trial that investigated the efficacy of fluvastatin after a successful first PCI (1). 
Methods A total of 1,677 patients with stable and unstable angina or silent ischemia 
were randomized to receive treatment with fluvastatin 80 mglday (40 mg twice daily) 
(n=322 with multivessel disease, n=522 with single-vessel disease) or matching placebo 
(n=292 with multivessel disease, n=541 with smgle-vessel disease) after their first suc- 
cessful PCI. 
Results: In placebo controls with multivessel disease, the incidence of MACE was 
33.9% as compared to 22.7% in those with single-vessel disease. Fluvastahn signifi- 
cantly reduced the risk of MACE in patients with multivessel disease by 34% (RR, 0.66; 
95% Cl. 0.48-0.91: ~=0.01) compared with vlacebo: patients with sinale-vessel disease 
had a 14% risk reduction (RR, 0.86; 95% Cl, 0.66-l .13; p=O.28). When restenotlc compli- 
cations m the first 6 months post-PC1 were excluded. fluvastatin sianificantlv reduced the _ 
risk of MACE by 42% (RR, 0.58; 95% Cl. 0.48-0.91; p=O.O02) in patients with multivessel 
disease compared with placebo; patients with single-vessel disease had a risk reduction 
of 23% (RR, 0.77; 95% Cl, 0.57-1.03; p=O.O7). 
Conclusion: Fluvastatin significantly reduces the risk of MACE after PCI in patients with 
multivessel disease compared with placebo. 
1. Serruys PWJC. et al. JAMA 2002;287:3215-22. 
